NCT07132567 Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
| NCT ID | NCT07132567 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kyowa Kirin Co., Ltd. |
| Condition | Mycosis Fungoides |
| Study Type | OBSERVATIONAL |
| Enrollment | 15 participants |
| Start Date | 2025-05-02 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15 participants in total. It began in 2025-05-02 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.
Eligibility Criteria
Inclusion Criteria: 1. Adults 19 years of age or older 2. Individuals who are confirmed to have received administration of the study drug for the purpose of "the treatment for adult patients with fungoidal granuloma or Sezary syndrome who have received one or more systemic therapies," or who are considered to require administration of the study drug in the investigator's opinion 3. Individuals who (or whose legally acceptable representatives) signed the Consent to Use of Personal Information of their own free will for participation in this use-result surveillance Exclusion Criteria 1. Patients with hypersensitivity to any ingredients of this drug 2. Patients who intend to use this drug for non-approved indications 3. Patients who participated in a pre-market clinical trial of the study drug and received administration of the study drug
Contact & Investigator
Hyejin Noh
STUDY DIRECTOR
Kyowa Kirin Korea Co., Ltd.
Frequently Asked Questions
Who can join the NCT07132567 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Mycosis Fungoides. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07132567 currently recruiting?
Yes, NCT07132567 is actively recruiting participants. Contact the research team at hyejin.noh.2u@kyowakirin.com for enrollment information.
Where is the NCT07132567 trial being conducted?
This trial is being conducted at Busan, South Korea, Seoul, South Korea, Seoul, South Korea, Seoul, South Korea and 2 additional locations.
Who is sponsoring the NCT07132567 clinical trial?
NCT07132567 is sponsored by Kyowa Kirin Co., Ltd.. The principal investigator is Hyejin Noh at Kyowa Kirin Korea Co., Ltd.. The trial plans to enroll 15 participants.